Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
Risks for MACE, MI, cardiovascular death, heart failure, all-cause mortality lower versus DPP-4 inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.